Savella relieves symptoms of fibromyalgia.1

Delivers simultaneous improvements on 3 measures of fibromyalgia1

• Pain reduction
• Improvement in patient global fibromyalgia assessment
• Improvement in physical function

Decrease in pain as early as week 1 of treatment with a stable dose in some patients who reported global improvement1

• Primary endpoint was assessed at week 15.

Low potential for pharmacokinetic drug-drug interactions1

• Clinically important pharmacodynamic interactions may occur with MAOIs, serotonergic drugs (including other SSRIs, SNRIs, lithium, tryptophan, antipsychotics, and dopamine antagonists), triptans, catecholamines (epinephrine and norepinephrine), CNS-active drugs (including clomipramine), and select cardiovascular agents (IV digoxin and clonidine).

A dual reuptake inhibitor that blocks the reuptake of norepinephrine over serotonin with approximately 3 times greater potency in vitro1

• The clinical significance of in vitro data is unknown.

Savella is widely available on managed care formularies.3

NEXT: Learn about the clinical studies on Savella